BioSpace News Archive

Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“ Aleafia Health ” or the “ Company ”) will announce on August 11 prior to market open its fiscal year 2023 first quarter results for the period ending June 30, 2022.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company’s operations. 

Navidea Biopharmaceuticals, Inc. today announced that the subscription period for the previously announced rights offering has commenced.

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis (AD).

Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, reported financial results for the second quarter ending June 30, 2022, and recent program highlights.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review additional analyses from the preclinical and Phase 1 clinical studies of CRN04894 in an oral presentation at the 10th International Congress of Neuroendocrinology (ICN), being held August 7-10, 2022.

PDS Biotechnology Corporation (Nasdaq: PDSB), today announced that its independent Data Monitoring Committee (DMC) met for its scheduled review of PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the potential treatment of recurrent or metastatic HPV16-positive head and neck cancer.

Mesa Laboratories, Inc. announced results for its first fiscal quarter.

Today, the Bladder Cancer Advocacy Network, (BCAN), announced its first-ever Translational Clinical Trial Award (TCTA) to support patient-oriented research to transform bladder cancer care.